Eli Lilly's mirikizumab improves fatigue in patients with Crohn's disease in Phase 2 trial

Eli Lilly reports data from Phase 2 SERENITY study evaluating mirikizumab compared to placebo in patients with moderately to severely active Crohn's disease (CD) at 12 weeks.